{"": [83, 92, 0, 93, 1903, 0], "Introduction": [1904, 4245, 0], "Cell Entry, Cell Pyroptosis and NETosis": [4298, 9703, 0], "PAMPS/TLR Interaction and the IFN Response": [9704, 15007, 0], "Cytokine Release Syndrome and Immunopathology": [15008, 18941, 0], "Epitope Specificity of T-Cells": [20440, 22417, 0], "T-Cell Populations and Disease Severity": [22418, 32774, 0], "T-Cell Responses to SARS-CoV-2": [18942, 32774, 1], "Epitope Specificity of B-Cells": [32807, 33932, 0], "B-Cell Populations and Disease Severity": [33933, 36942, 0], "Anti-SARS-CoV-2 Neutralizing Antibody Titre and Kinetics": [36943, 41278, 0], "Effector Functions of Antibodies and Risk of ADE": [41279, 44089, 0], "Autoantibodies Against Type I Interferons": [44090, 45490, 0], "B-Cell Responses to SARS-CoV-2": [32775, 45490, 1], "SARS-CoV-2 Infection and the Inflammatory Response": [4246, 45490, 1], "Trained Innate Immunity": [46870, 49808, 0], "Serological Immune Imprinting": [49809, 52482, 0], "Preexisting CD4+T-Cell Immunity": [52483, 53709, 0], "Prior Infections/Vaccines and Cross-Reactive Immunity": [45491, 53709, 1], "Vaccine Development": [53753, 55686, 0], "Therapeutic Antibodies": [55687, 59485, 0], "Cell-Based Therapies": [59486, 61319, 0], "Immunosuppressants and Other Therapeutic Modalities": [61320, 65221, 0], "Immunotherapeutic Approaches for Covid-19": [53710, 65221, 1], "Conclusion": [65222, 67393, 0]}